A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma
Trial status:Recruiting
Study Identifier:
GO44479
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genentech, Inc.
Recruiting
Trial details
Medical Condition
Study Drug
Phase
Phase 2
Sex
Female & Male
Age
18+
Estimated Trial Date
Oct 2023 - Dec 2029
Protocol summary
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Trial locations
Location
Status
Location
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Status
Recruiting
Location
USC Norris Cancer Center; USC Oncology Hematology Newport Beach
Newport Beach, California, United States, 92663
Status
Recruiting
Location
University of California, San Francisco (UCSF)
San Francisco, California, United States, 94143
Status
Recruiting
Location
University of California Los Angeles
Santa Monica, California, United States, 90404
Status
Recruiting
Location
St. Francis Hospital and Medical Center
Hartford, Connecticut, United States, 06105
Status
Recruiting
Location
Smilow Cancer Center
New Haven, Connecticut, United States, 06510
Status
Withdrawn